immunohistological staining detected human CD3+ cells in the murine spleen and liver. Lymphocytes ''home'' to the white pulp T cell area and to the red pulp; localization in the liver is prevalently at periportal area. PCR confirmed cytofluorimetric and immunohistological results. After gcv treatment (day +19) cytofluorimetric analysis showed very few CD3+ cells. Scattered human CD3+ cells were detected by immunohistology. PCR identified the transgene in 22% of all tissue samples (only thymic and splenic samples were positive). GvHD did not occur in any animal. These data clearly demonstrated: 1) elevated doses of human CD3+ cells engraft in NOD/SCID mice; 2) after gcv treatment very few CD3+ cells can be detected by cytofluorimetric analysis, immunoistological staining and PCR; 3) these rare lymphocytes, which escape treatment, can be detected in the thymus and in the spleen at day +19 in 22% of tissues samples. Lack of full response to gcv, as demonstrated in this study, may account for cases of GvHD in patients receiving tk-transduced T lymphocytes.
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O268
Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T-lymphocyte phenotype and functions D. Sauce, N. Tonnelier, A. Duperrier, B. Petracca, M. de Carvalho Bittencourt, P. Saas, C. Ferrand, P. Hervé, P. Tiberghien, E. Robinet (Besançon, F) Alloreactive T cells present in an hematopoïetic stem cell (HSC) graft have both beneficial properties (anti-viral, anti-leukemic and engraftment-facilitating effects) and negative ones, such as the induction of graft-versus-host disease (GvHD). In order to modulate the alloreactivity after HSC transplantation, we have initiated a clinical study aimed at infusing suicide gene-expressing donor T cells together with an allogeneic T-cell-depleted HSC graft. Such gene-modified cells (GMC) can be specifically depleted in vivo by ganciclovir administration, if a GvHD occurs. Immune competence of such cells is a critical issue. We have examined the impact of the ex vivo gene transfer protocol (12-day culture period including CD3 / IL-2 activation, retroviral-mediated gene transfer and G418-based selection) on the phenotype and functional properties of GMC. GMC were compared with control (Co) cells that had been cultured in parallel with GMC, but non transduced and non selected, as well as with PBMC. Our data show that phenotypical modifications are similar in Co cells and GMC, demonstrating that alterations results from the 12-day culture rather than from the transduction and/or selection process itself. Such modifications include a reversal of CD4/CD8 ratio, activated phenotype (increased expression of CD45RO, CD95 and HLA-DR) and acquisition or increased expression of costimulatory molecules (CD80, CD80 and CD40). This increased expression was associated with an enhanced allostimulating potential of GMC, as compared with resting T cells, when GMC were used as stimulating cells in mixed lymphocyte reactions (MLR). Conversely, when using them as responder cells in MLR, GMC exhibited a strong loss of alloreactivity that was a culturerelated event, since it occured as soon as three days after PBMC activation. The impaired alloreactivity of GMC was not due to alloantigen-mediated, activation-induced cell death upon MLR initiation. Indeed, the percentage of CD3+ apoptotic cells did not increase after activation by irradiated stimulating cells and proliferative response of GMC in MLR was not improved by addition of exogenus blocking CD95 antibody. In conclusion, the retroviral-mediated gene transfer is associated with major phenotypical and functional alterations that result mainly from the ex vivo culture. Thus, future T cell expansion protocols should not only try to improve cell proliferation or gene transfer efficiency, but also try to preserve T-cell functions.
Solid Tumors
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High-dose chemotherapy with hematopoietic stem cell support for germ cell tumors: the Italian experience G. Rosti, U. De Giorgi, R. Salvioni, G. Papiani, L. Sebastiani, M. Argnani, G. Monti, P. Ferrante, G. Pizzocaro, M. Marangolo (Ravenna, Milan, I) Objectives: In the last years, high-dose chemotherapy (HDCT) with hematopoietic stem cell support (HSCS) has become a therapeutic option for germ cell tumors (GCTs) with more than 300 patients treated in Europe each year. We report the experience at (Beyer et al 1996) . Fifteen poor prognosis patients at the diagnosis (IGCCCG staging system) were treated as late intensification of first-line chemotherapy. Results: Eleven (73%) poor prognosis patients who received HDCT in first-line setting and 28 (33%) patients treated with HDCT as salvage therapy are continuously disease-free. In the good risk group, 24 patients (69%) are continuously disease-free, compared with 4 (13%) in the intermediate risk group (P < .001), and no one in poor risk group (P < .001). Treatment-related mortality occurred only in the poor risk (n = 6), and intermediate risk groups (n = 4). Conclusions: In our experience, HDCT induced impressive longterm remissions either in first-line setting or as salvage treatment in good risk patients. Moreover, use of validate prognostic classifications may contribute to better define the role of HDCT besides improving the outcome of patients with GCT. The definitive statement on the possible role of HDCT in GCT will derive from the ongoing phase III randomized studies. This study was supported by a fellowship from Istituto Oncologico Romagnolo.
O270
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients X. Durando, J. Lemaire, P. Verrelle, R. Plagne, J. Bay (ClermontFerrand, F) Conventional treatments of high-grade gliomas include maximal neurosurgery resection followed by external radiation therapy. Despite these treatments, the prognosis for patients is poor. Survival of more than one year is exceptional. Using high-doses of chemotherapy might be another way to increase the response rate and the median survival. Increasing doses of BCNU might be more effective but also provokes unacceptable myelotoxicity. This dose-limiting toxicity can be circumvented by using autologous marrow or peripheral blood stem cell rescue. We here report our experience of high-dose BCNU followed by transplantation of autologous hematopoietic stem cells from marrow or peripheral blood in 114 patients with high-grade gliomas. Of the 114 gliomas, 78 were glioblastoma multiforme (GM) (68 %), 24 anaplasis astrocytomas (21 %), and 12 malignant oligodendrogliomas (OD) (11 %). Complete neurosurgical resection was performed for 22 patients (18 GM and 4 AA). The mean age was 44 years. Eighty-four patients received autologous hematopoietic stem cell from bone marrow harvest while 30 patients underwent granulocyte colony stimulating factor followed by apheresis and received peripheral blood progenitor cells (PBPC). High-doses of BCNU (800mg/m2) were given at least one month after neurosurgery. Bone marrow or PBPC were transplanted 48 to 72 hours after chemotherapy. Radiotherapy was started approximately 40 days after transplantation. A total of 60 Gy were delivered. The overall survival (OS) median and time to treatment failure (TTF) median were respectively 15 months and 9 months (p=0.01). The histology type appears to be the main discriminating factor, with the worse prognosis with GM. More specifiquely in the GM population, the age, the completeness of surgery, and the response rate appear to be important prognosis factors. Seventyone patients started chemotherapy with a mesurable tumor (44 GB, 19 AA, and 8 OD). After a mean of 71 days after radiotherapy, we observed 9 complete responses and 14 partial responses, while the others were stable or in progression. OD tumors had the highest response rates, with seven of eight patients responding.
The protocol thus appears to be feasible and without major risks to the patients. The OS and TTF seem to be better than that described for other treatments. However, a larger and randomized study should be performed in order to confirm these results.
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Autologous peripheral blood stem cell rescue permits administration of high activities of rhenium-186 HEDP in progressive hormone refractory prostate cancer metastatic to bone J. O'Sullivan, J. Treleaven, V. McCready, A. Norman, A. Horwich, R. Huddart, D. Dearnaley (London, UK) Background: Autologous peripheral blood stem cell rescue was used in patients with progressive hormone refractory prostate cancer metastatic to bone to test the feasibility and toxicity of high activities of a bone seeking radionuclide, Rhenium-186 Hydroxyethylidene Diphosphonate (HEDP), in an a phase I trial. Thrombocytopenia has been identified as the dose limiting toxicity of Rhenium-186 in previous studies. We hypothesised that by increasing the administered activity using peripheral blood stem cell rescue to prevent marrow failure, it would be possible to increase the ionising radiation dose to individual metastases, which might ablate small lesions and reduce new lesion formation. Materials and Methods: Peripheral blood stem cells were harvested at least 2 weeks before radio-isotope treatment following mobilisation by G-CSF. Stem cells were returned 14 days after Rhenium-186 HEDP. Unacceptable toxicity was defined as grade III haematological toxicity, lasting at least 7 days, or grade IV haematological toxicity of any duration or any serious unexpected toxicity. Twenty five patients with progressive hormone refractory prostate cancer metastatic to bone were treated in a phase I study. Results: Two patients out of an expanded group of 6 who received 5000MBq experienced grade III thrombocytopenia, which recovered within 10 days in both cases. No unexpected serious toxicity occurred. The platelet nadir occurred at a median of 21 days. An activity limiting toxicity at 5000MBq was defined. Conclusions: Activities of 5000MBq of Rhenium-186 HEDP are feasible using autologous peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone. The main toxicity is thrombocytopenia, which is short lasting. The potential exists for the delivery of high doses of ionising radiation to individual bone metastases. We have now commenced a Phase II trial to further evaluate response rates.
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High-dose chemotherapy in children with nephroblastoma B. Kremens, B. Gruhn, C. Hasan, T. Klingebiel, H. Laws, E. Koscielniak, F. Berthold, N. Graf (Essen, Jena, Bonn, Frankfurt, Duesseldorf, Stuttgart, Cologne, Homburg, D) From April 1992 to December 1998, 27 children with renal tumors received high dose chemotherapy (HDC) with autologous stem cell rescue in Germany, 25 of whom had nephroblastoma and were evaluable. Thirteen boys and 12 girls had a median age of 64 months (11-210) at diagnosis and of 78 months (26-260) at HDC. At diagnosis, 14/25 had stage IV and 15 stage I -III. Histology was standard in 14, high-grade in 5, completely necrotic after treatment in 4 and nephroblastoma without further specification in 2 patients. Reasons for HDC were: relapse/progression with initial s tage IV (10), second or subsequent relapse (8), bone or brain metastases (2), relapse in irradiated region, extraregional lymph node involvement, unfavourable histology, early relapse and clear cell sarcoma in first remission (1 patient each). At time of HDC, the disease was in CR in 15 and in PR in 10 children. The creatinine clearance at this time was 102 ml/min/1.73m² (mean; SE 43). Conditioning included etoposide 1000 mg/m², melphalan 180 mg/m² and carboplatin in an AUC-targeted dose according to Calvert (JCO 1989 (JCO , 7:1748 in 20 patients. Four children had other melphalan-based regimens without carboplatin, one child was treated with etoposide, thiotepa and cyclophosphamide. There were no treatment related deaths. Progression or relapse occured in 12 children after three months (median; range 5-75). Overall survival was 58% and EFS 51%. Intermittent hemodialysis was needed for 1 patient. Reversible abnormal serum creatinine was noted in 6, tubular dysfunction in 5 of 21 evaluable patients. High dose chemotherapy with carboplatin, etoposide and melphalan appears to be a valuable treatment option for patients with high-risk, mainly recurrent nephroblastoma. With adjustment of the carboplatin dose to glomerular function, the risk of kidney damage is limited.
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Nonmyeloablative hematopoietic stem cell transplantation for metastatic solid tumors L. Barkholt, P. Hentschke, M. Uzunel, J. Mattsson, M. Remberger, P. Wersäll, P. Pisa, J. Martola, N. Albiin, A. Wernerson, M. Söderberg, A. Thörne, O. Ringdén (Stockholm, S) Objective: Does allogeneic hematopoietic stem cell transplantation (ASCT) have an anticancer effect in patients with solid tumors? Methods: In total 18 patients, six with colorectal (C1-6), ten with renal (R1-10), one with breast (B1) adenocarcinoma and one with cholangiocarcinoma in liver hilum (L1), and metastases in all, underwent ASCT. Conditioning included Fludarabine 30 mg/m2 for 3 days, using sibling donors (C1-6, R3, 7-10 and L1), and 5 days using unrelated donors followed by 2 Gy total body irradiation. Antithymoglobulin 4 mg/kg was administrated to patients with unrelated donors (n=6). Peripheral blood stem cells were collected after G-CSF stimulation of all donors. The CD34+ cell dose was median 7.5x10(6)/kg (1.7-21.8). Treatment was usually given on an outpatient basis. Immunosuppression was by mycophenolate mofetil and cyclosporine. Chimerism was determined using PCR amplification of variable number tandem repeats. Results: Twelve patients became 100% donor chimeras within a median of 28, 49 and 65 days for B -, myeloid and T cells, respectively. Two patients rejected the grafts, 1 developed total marrow aplasia and 3 were mixed chimeras. During the first month, 7 patients were given erythrocyte transfusions. Two patients had hemolysis for 3 and 9 months after HSCT, respectively. No platelet transfusions were needed. Only a transient decrease in platelet count (<50x109/L) and/or total WBC (<2x109/L) was seen in 8 patients. Bacterial septicemia, CMV reactivation and syndrome developed in 2, 14 and 4 patients, respectively. The cumulative incidence of grades II-IV acute GVHD was 57%. Tumor regression of all metastases was seen in one patient with colon carcinoma. Another patient with colon and 2 with renal adenocarcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. One patient with renal cell carcinoma, who died of severe aGVHD, showed necrosis of metastases in the lung. Ten patients died; 4 of transplant-related complications, 1 of head trauma and 5 of progressive disease. Eight patients are alive between 3.5 and 13 months. Conclusion: Following ASCT with reduced conditioning and GVHD, total or partial regression of metastases was seen in 2 patient with colon and 3 patients with renal adenocarcinoma. The regression of some metastases associated with GVHD provides suggestive clinical evidence that the graft-versus-tumor effect may occur in colon and renal adenocarcinoma.
O274 Allogeneic immunotherapy for solid tumors (ST) : a feasibility trial
J. O. Bay, M. Michallet, J.M. Boiron, J.Y. Cahn, N. Ifrah, J.J. Sotto, N. Gratecos, C. Faucher, J.Y. Blay, D. Olive, D. Maraninchi, P. Viens, D. Blaise (Clermont-Ferrand, Lyon, Pessac, Besançon, Angers, Grenoble, Nice, Marseille, F) Despite recent advances in chemotherapy and other forms of immunotherapy, a large number of pts suffering from ST always die from disease progression. In hematology, allo stem cell transplantation (ASCT) has shown for decades its potential to eradicate malignancies. Due to its high level of TRM, it has however been restricted to some indications. Recent modalities based on chemotherapy reduced intensity regimen prompted us to assess the relevance for ST. Primary goal of this trial was to demonstrate an acceptable toxicity in this field and to optimize procedure. On October 2001, 35 patients with very advanced and heavily pretreated diseases have been included in 8 centers : Renal cell (13); Breast (8); Melanoma (4); Ovarian (4); Colo-rectal (2); Others (5). Median age : 44 (28-60) and M/F : 17/18. 3 pts progressed and died prior to starting conditioning. 32 pts were transplanted from an HLA identical sibling (BM :9; PBSC :26). Preparation consisted of Fludarabine (30 mg/m²x6), Busulfan (1mg/kgx8) and ATG (Thymoglobuline : 2.5 mg/kg/d) : Dose of ATG was progressively decreased to lower infections and increase alloreactivity (4 days : 2; 3 days : 6; 1 day : 24). Early course was uneventful. After documented engraftment, and depending upon tumoral evaluation, most of the patients had reduction of post graft CSA with possible subsequent DLI. Overall grade 2-4 GVHD was 31 %. TRM occurred in one patient (GVHD after CSA withdrawal). At time of abstract, response evaluation is still under investigation but at least 3 of the first 14 pts presented a response (renal and ovarian carcinoma (2)). Complete evaluation of transplant course (hematological and immune recovery; chimerism evolution; GVHD evaluation), immunomodulation (CSA variation and DLI) and response are under analysis and will be presented for patients with a minimal follow-up of 6 months. However first conclusions can be drawn: 1) TRM is minimal 2) Pts with very active disease are very unlikely to be controlled by this approach: pre graft tumor kinetic must be slowed down 3) Conditioning immunosuppression can be still lowered and we are presently decreasing the dose of Fludarabine 4) Early post graft immunomodulation is crucial (notably for CSA diminution) to reach early and good level of antitumor alloreactivity. 5) Not all diseases seem to have the same level of sensibility to this approach (high : Renal, ovarian and colorectal Ca; low : melanoma)
Graft Engineering
O275
A validated, reproducible and sensitive quantitative assay for the detection of residual B Cells after purging of stem cell collections using the ELIGIX(tm) B cell -SC cell separation system S. Martin, R. Schmittling, K. Pennline, R. Monroy (Brentwood, Medford, USA) Cell separation technologies have been developed to purge B cells from autologous stem cell (SC) products to rescue nonHodgkin's lymphoma (NHL) patients after high dose chemotherapy. A PCR assay for bcl-2/IgH, t(14;18) rearrangement is frequently used to detect residual malignant cells after purging; however, not all SC products of NHL patients are evaluable by PCR. Furthermore, in existing validated PCR assays, the limit of detection ranges between 1 and 10 tumor cells per 106 cells. A predominant BCell surface marker presentation NHL tumor cells is CD20. Therefore, an immunocytochemistry (ICC) assay directed against CD20 was developed using the ChromaVision Automated Cellular Imaging System (ACIS) which provides quantitative analysis of residual B cells in SC products after purging with the Eligix (superscript: TM) BCell-SC Cell Separation System. Using SC products, pre and post B cell purging, large format cytospin slides were prepared using 1.2 x 106 cells each, where a mean of 6.1 x 105 1.2 x 104 cells (N=147) were counted per slide. Staining was optimized to discriminate individual cell morphology, proper chromagen intensity, and minimal background stain. The total number of cells counted on a slide was validated based upon ACIS and estimated manual cell counts. The analyses were shown to be reproducible within multiple re-counts and over time. Slides were prepared containing a titration of residual B cells and analysis demonstrated a linearity of detection for residual B cells over the range of 200 to 0.3 B cells per 106 total cells, establishing the limit of detection at 0.3 B cells /106 cells. To insure reproducibility and sensitivity, multiple slides (7-10), collectively containing > 3 x 106 cells, were prepared for each sample. Since the assay was developed for rare event detection, the accuracy is resolved at higher B cell frequencies >0.5%. The ICC assay has been successfully used to detect residual B cells after purging of SC products from normal volunteers and patients demonstrating 3-6 log B cell depletions. An important valued asset of the assay is its ability to quantitate B cells in patient SC products prior to purging, where the B cell frequency is below the detection limits of flow cytometry. This enables quantitation of the efficiency of B cell purging. We have demonstrated a validated ICC assay that can quantitatively detect as few as 0.3 B cells per 106 cells and can be readily applied to the analysis of residual B cells for all NHL patient stem cell products purged of B cells.
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Selective allodepletion by immunomagnetic sorting can reduce alloreactivity in vitro, can be done at a clinical scale and preserves in vitro activity against CMV and EBV.
J.K. Davies, M.B. Koh, H.G. Prentice, M.W Lowdell (London, UK)
Graft versus host disease (GvHD) is a cause of significant morbidity and mortality in haematopoietic stem cell transplantation. In the HLA matched setting GvHD can be effectively prevented by pan T cell depletion, but the profound level of T cell depletion required to do so in non-HLA matched transplantation leads to an unacceptable delay in immune reconstitution and an increase in post transplant infections. We have developed a method of selective depletion of alloreactive cells based on the coculture of irradiated recipient mononuclear cells and donor cells in a modified mixed lymphocyte reaction (mMLR). Alloreactive donor cells are identified by their increased expression of the early activation antigen CD69 and these cells
